For millions of Americans living with obesity and Type 2 diabetes, a new class of medications has brought renewed hope. Drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound have changed the way physicians treat chronic weight-related conditions, helping many patients lose significant amounts of weight while improving blood sugar control. Yet as prescriptions continue to climb, medical experts say the nation is only beginning to understand the long-term implications of these medications, particularly for children, older adults, and underserved communities. During a recent national news briefing, leading physicians and researchers discussed both the remarkable promise and the unanswered questions surrounding GLP-1 medications.
More Than Weight Loss
Dr. Jena Shaw Tronieri of the University of Pennsylvania explained that GLP-1 medications work by changing the biological signals that regulate hunger rather than relying solely on willpower or calorie counting. She noted that many patients experience what has become known as the disappearance of “food noise,” describing a significant reduction in constant thoughts about eating. “Patients describe how different weight loss feels with the GLP-1s compared to dieting alone,” she said. “Instead of carefully tracking every calorie, they notice their portions are smaller, and food is simply not on their mind as much.”
Her team’s research found that while feelings of hunger may gradually return after several months, patients generally continue consuming fewer calories and maintain meaningful weight loss as long as they remain on the medication. However, she warned that many patients discontinue treatment because of cost, side effects, or insurance issues. “About two thirds of the weight that they had lost is regained in the first year after they stopped taking the GLP-1 medication,” Tronieri said, emphasizing that obesity should be treated like other chronic diseases requiring long-term management rather than a temporary intervention.
Access Remains Unequal
While medical advances have expanded treatment options, access continues to be a major obstacle. Dr. Fatima Cody Stanford of Harvard Medical School argued that obesity is far more complex than poor lifestyle choices. She described it as “a disease of energy regulation” shaped by genetics, hormones, stress, environmental conditions, and social factors accumulated over generations.
Stanford also highlighted the financial challenges many patients face. Although new federal programs have reduced costs for some Medicare beneficiaries, she explained that complicated approval requirements and inconsistent insurance coverage continue to prevent many eligible patients from receiving treatment. “The patients from lower socioeconomic positions who seem to have the highest burden of disease are not getting access to these agents,” she said. She stressed that effective public policy must ensure that medical need, rather than income or geography, determines who benefits from these therapies.
Questions About Young People
One of the strongest cautions came from pediatric specialist Dr. Dan Cooper of the University of California, Irvine. While acknowledging that some children with severe obesity may benefit from medication, Cooper warned that adolescence is a unique stage of physical development when muscles, bones, and the brain are still growing.
“We have to be really, really careful and thoughtful about using these medications in children and adolescents,” Cooper said. He expressed concern that researchers still do not fully understand how long-term use may affect developing bodies. Rather than relying primarily on medication, he called for greater investment in physical education, healthier communities, parks, and comprehensive lifestyle programs that encourage lifelong healthy habits. “If we don’t do that, then I think it’s ethically wrong to put kids on these medications alone,” he added.
A Personal Perspective
Journalist Jasmyne Cannick shared her own experience with GLP-1 therapy, reminding listeners that behind the medical research are individuals seeking healthier lives. Her story illustrated that treatment decisions are deeply personal and should be made in partnership with knowledgeable healthcare providers while considering both the benefits and potential risks.
Why This Matters
Obesity affects millions of families across the United States and contributes to higher rates of diabetes, heart disease, sleep apnea, and other chronic illnesses. These conditions also disproportionately affect many underserved and immigrant communities where access to preventive care and specialty treatment is often limited. As GLP-1 medications become increasingly common, community members will need reliable medical information to distinguish scientific evidence from social media hype.
The experts agreed that these medications represent an important medical breakthrough, but they are not a cure-all. Successful treatment requires careful medical supervision, healthy nutrition, physical activity, and equitable access to care. As research continues, physicians hope that the conversation will shift beyond weight loss alone toward improving long-term health and quality of life for patients of every age.